Add to ORKGlocated on the World Wide Web at: The online version of this article, along with updated information and services, is by guest on M arch 3, 201
Objective: The efficacy and safety of weekly administration of epoetin beta (EPO) for chemotherapy-i...
Objectives: To update the 2006 systematic review of the comparative benefits and harms of erythro...
Limited data are available to describe the effectiveness of darbepoetin alfa (DA) in terms of hemogl...
Background: Patients receiving chemotherapy often develop anemia. Darbepoetin alfa (Aranesp(TM)) is ...
Background: Patients receiving chemotherapy often develop anemia. Darbepoetin alfa (Aranesp™) is an ...
located on the World Wide Web at: The online version of this article, along with updated information...
Anemia is common in patients with cancer or myelodysplastic syndrome. Erythropoietic therapy offers ...
In part A of this study, patients were randomised to cohorts receiving darbepoetin alfa at doses of ...
is often used to treat patients with chemotherapy-induced anemia using weekly or every-2-week admini...
Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controll...
The aim of this thesis was to determine the relevant dose of arbepoetin-alfa (DA) in patients with l...
A group of 62 patients with different advanced cancers and with an anaemic condition were treated wi...
Prior to the approval of the first erythropoiesis-stimulating agent (ESA) in the early 1990s, red bl...
located on the World Wide Web at: The online version of this article, along with updated information...
Anemia has a high prevalence and incidence in patients with cancer and is associated with a range of...
Objective: The efficacy and safety of weekly administration of epoetin beta (EPO) for chemotherapy-i...
Objectives: To update the 2006 systematic review of the comparative benefits and harms of erythro...
Limited data are available to describe the effectiveness of darbepoetin alfa (DA) in terms of hemogl...
Background: Patients receiving chemotherapy often develop anemia. Darbepoetin alfa (Aranesp(TM)) is ...
Background: Patients receiving chemotherapy often develop anemia. Darbepoetin alfa (Aranesp™) is an ...
located on the World Wide Web at: The online version of this article, along with updated information...
Anemia is common in patients with cancer or myelodysplastic syndrome. Erythropoietic therapy offers ...
In part A of this study, patients were randomised to cohorts receiving darbepoetin alfa at doses of ...
is often used to treat patients with chemotherapy-induced anemia using weekly or every-2-week admini...
Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controll...
The aim of this thesis was to determine the relevant dose of arbepoetin-alfa (DA) in patients with l...
A group of 62 patients with different advanced cancers and with an anaemic condition were treated wi...
Prior to the approval of the first erythropoiesis-stimulating agent (ESA) in the early 1990s, red bl...
located on the World Wide Web at: The online version of this article, along with updated information...
Anemia has a high prevalence and incidence in patients with cancer and is associated with a range of...
Objective: The efficacy and safety of weekly administration of epoetin beta (EPO) for chemotherapy-i...
Objectives: To update the 2006 systematic review of the comparative benefits and harms of erythro...
Limited data are available to describe the effectiveness of darbepoetin alfa (DA) in terms of hemogl...